- 全部删除
您的购物车当前为空
ORY1001 (ORY 1001) 是一种具有口服活性的选择性赖氨酸特异性去甲基化酶 LSD1/KDM1A 抑制剂,对相关的 FAD 依赖性氨氧化酶具有高选择性,IC50 <20 nM。

ORY1001 (ORY 1001) 是一种具有口服活性的选择性赖氨酸特异性去甲基化酶 LSD1/KDM1A 抑制剂,对相关的 FAD 依赖性氨氧化酶具有高选择性,IC50 <20 nM。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 410 | In stock | |
| 2 mg | ¥ 737 | In stock | |
| 5 mg | ¥ 1,320 | In stock | |
| 10 mg | ¥ 2,380 | In stock | |
| 25 mg | ¥ 3,960 | In stock | |
| 50 mg | ¥ 5,760 | In stock | |
| 100 mg | ¥ 7,860 | In stock | |
| 500 mg | ¥ 15,800 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 1,320 | In stock |
ORY1001 相关产品
| 产品描述 | ORY1001 (ORY 1001) is an orally active and selective lysine-specific demethylase LSD1/KDM1A inhibitor, with high selectivity against related FAD dependent aminoxidases with IC50 of <20 nM. |
| 靶点活性 | LSD1/KDM1A:20 nM |
| 体外活性 | 在THP-1 (MLL-AF9) 细胞中,ORY-1001 引起依时间/剂量依赖的方式,在KDM1A 目标基因上累积me2H3K4,并伴随分化标志物的诱导。ORY-1001 也诱导THP-1细胞的凋亡,并抑制MV(4;11) (MLL-AF4) 细胞的增殖和集落形成。[1] |
| 体内活性 | 在啮齿类MV(4;11)异种移植瘤模型中,ORY-1001(<0.020 mg/kg,p.o.)显著抑制了肿瘤生长。[1] |
| 别名 | RG-6016, ORY-1001, ORY 1001 |
| 分子量 | 303.27 |
| 分子式 | C15H22N2·2HCl |
| CAS No. | 1431326-61-2 |
| Smiles | Cl.Cl.NC1CCC(CC1)N[C@@H]1C[C@H]1c1ccccc1 |
| 密度 | no data available |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 10 mg/mL (32.97 mM), Sonication is recommended. Ethanol: 1 mg/mL (3.3 mM), Sonication is recommended. H2O: 56 mg/mL (184.65 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO/H2O
DMSO/H2O
H2O
| ||||||||||||||||||||||||||||||||||||||||||||||
评论内容